Ariad Pharmaceuticals Inc., of Cambridge, Mass., and Otsuka Pharmaceutical Co. Ltd., of Tokyo, said they entered an agreement for Otsuka to commercialize Ariad's Iclusig (ponatinib) in Japan and nine other Asian countries and to fund future clinical trials in those regions.